Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2020 Filed Jul 7, 2020 00:18 UTC |
Nash DuaneDirector
|
GrantStock Option · Derivative | 45,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000800 · e619753_4-duane.xml · derivative · entry 1 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:17 UTC |
PHILLIPS BARCLAY ADirector
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000798 · e619751_4-phillips.xml · derivative · entry 1 PHILLIPS BARCLAY A · CIK 0001265801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:18 UTC |
HOWSON TAMAR DDirector
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000799 · e619752_4-howson.xml · derivative · entry 1 HOWSON TAMAR D · CIK 0001202286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:17 UTC |
Neermann JoergDirector
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000797 · e619750_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:16 UTC |
Whaley GlennPAO and PFO
|
GrantStock Option · Derivative | 30,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000795 · e619748_4-whaley.xml · derivative · entry 1 Whaley Glenn · CIK 0001724623 · PAO and PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: 7,500 of the shares underlying the option (the "Underlying Shares") vest on the one-year anniversary of the grant date. Thereafter, 625 of the Underlying Shares vest on each successive one-month anniversary thereafter for the next thirty six (36) months. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:15 UTC |
Vitt DanielDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 80,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000793 · e619746_4-vitt.xml · derivative · entry 1 Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: 20,000 of the shares underlying the option (the "Underlying Shares") vest on the one-year anniversary of the grant date. Thereafter, 1,690 of the Underlying Shares vest on the thirteen (13) month anniversary of the grant date, and 1,666 of the Underlying Shares vest on each successive one-month anniversary thereafter for the next thirty five (35) months. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:16 UTC |
van den Bossche JanDirector
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000796 · e619749_4-vdb.xml · derivative · entry 1 van den Bossche Jan · CIK 0001774052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:15 UTC |
Groeppel ManfredChief Operating Officer
|
GrantStock Option · Derivative | 30,000 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001193805-20-000794 · e619747_4-groppel.xml · derivative · entry 1 Groeppel Manfred · CIK 0001773674 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: 7,500 of the shares underlying the option (the "Underlying Shares") vest on the one-year anniversary of the grant date. Thereafter, 625 of the Underlying Shares vest on each successive one-month anniversary thereafter for the next thirty six (36) months. Read SEC document |
| April 29, 2020 Filed May 1, 2020 01:41 UTC |
Whaley GlennPAO and PFO
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $8.84 | $0.00 |
DisclosureSEC source: 0001193805-20-000538 · e619593_4-whaley.xml · derivative · entry 1 Whaley Glenn · CIK 0001724623 · PAO and PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-04-29 F1 · derivative.exercise_date: 3,750 of the shares underlying the option (the "Underlying Shares") vest on the one-year anniversary of the grant date. Thereafter, 330 of the Underlying Shares vest on the thirteen (13) month anniversary of the grant date, and 312 of the Underlying Shares vest on each successive one-month anniversary thereafter for the next thirty five (35) months. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 00:00 UTC |
Nash DuaneDirector
|
SaleCommon Stock | 4,400 | $6.96 | $30,624.00 |
DisclosureSEC source: 0001193805-19-001904 · e619223_4-duane.xml · nonDerivative · entry 3 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,032 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 00:00 UTC |
Nash DuaneDirector
|
Tax withholdingCommon Stock | 7,930 | $7.15 | $56,732.01 |
DisclosureSEC source: 0001193805-19-001904 · e619223_4-duane.xml · nonDerivative · entry 2 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,432 F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs granted to the Reporting Person. F3 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $7.1508 and $7.1572 per share. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:00 UTC |
Nash DuaneDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 22,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-19-001904 · e619223_4-duane.xml · derivative · entry 4 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864,159 Underlying: Common Stock · 22,157 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 11, 2019, the Reporting Person was granted 886,316 restricted stock units as consideration of cancelled stock options. Pursuant to the Reporting Person's amended RSU Agreement, RSUs that vested prior to April 22, 2019 were settled on December 2, 2019. F5 · derivative.expiration_date: On January 11, 2019, the Reporting Person was granted 886,316 restricted stock units as consideration of cancelled stock options. Pursuant to the Reporting Person's amended RSU Agreement, RSUs that vested prior to April 22, 2019 were settled on December 2, 2019. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:00 UTC |
Nash DuaneDirector
|
Exercise / conversionCommon Stock | 22,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193805-19-001904 · e619223_4-duane.xml · nonDerivative · entry 1 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| December 01, 2019 Filed Jan 10, 2020 21:06 UTC |
Whaley GlennPAO and Controller
|
GrantStock Option · Derivative | 15,000 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001193805-20-000028 · e619281_4-whaley.xml · derivative · entry 1 Whaley Glenn · CIK 0001724623 · PAO and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-12-01 F1 · derivative.exercise_date: 3,750 of the shares underlying the option (the "Underlying Shares") vest on the one-year anniversary of the grant date. Thereafter, 330 of the Underlying Shares vest on the thirteen (13) month anniversary of the grant date, and 312 of the Underlying Shares vest on each successive one-month anniversary thereafter for the next thirty five (35) months. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:53 UTC |
PHILLIPS BARCLAY ADirector
|
GrantStock Option · Derivative | 29,959 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001193805-19-001465 · e619202_4-phillips.xml · derivative · entry 1 PHILLIPS BARCLAY A · CIK 0001265801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2019-11-14 F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 21:02 UTC |
HOWSON TAMAR DDirector
|
GrantStock Option · Derivative | 29,959 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001193805-19-001345 · e619122_4-howson.xml · derivative · entry 1 HOWSON TAMAR D · CIK 0001202286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2029-10-11 F1 · derivative.exercise_date: The option to purchase 9,986 shares vests in monthly increments over a period of one year from the grant date, and the option to purchase 19,973 shares vests in monthly increments over a period of three years from the grant date. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 21:01 UTC |
Vitt DanielDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 65,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001193805-19-000700 · e618582_4-vitt.xml · derivative · entry 1 Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-08-01 F1 · derivative.exercise_date: 16,250 of the options vest on the one-year anniversary of the grant date. Thereafter, 1,360 of the options vest on the thirteen (13) month anniversary of the grant date, and 1,354 of the options vest on each successive one-month anniversary thereafter for the next thirty five (35) months. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 12:45 UTC |
Groeppel ManfredChief Operating Officer
|
GrantStock Option · Derivative | 20,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001193805-19-000702 · e618583_4-groppel.xml · derivative · entry 1 Groeppel Manfred · CIK 0001773674 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-08-01 F1 · derivative.exercise_date: 5,000 of the options vest on the one-year anniversary of the grant date. Thereafter, 440 of the options vest on the thirteen (13) month anniversary of the grant date, and 416 of the options vest on each successive one-month anniversary thereafter for the next thirty five (35) months. Read SEC document |
| July 22, 2019 Filed Jul 25, 2019 01:01 UTC |
van den Bossche JanDirector
|
GrantStock Option · Derivative | 29,959 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001193805-19-000674 · e618565_4-vdb.xml · derivative · entry 1 van den Bossche Jan · CIK 0001774052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2029-07-22 F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
| July 22, 2019 Filed Jul 25, 2019 01:00 UTC |
Patel Sanjay SChief Financial Officer
|
GrantStock Option · Derivative | 79,891 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001193805-19-000673 · e618568_4-sanjay.xml · derivative · entry 1 Patel Sanjay S · CIK 0001611708 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,891 Underlying: Common Stock · 79,891 shares Expires 2029-07-22 F1 · derivative.exercise_date: 19,987 of the options vest on the one-year anniversary of the grant date. Thereafter, 1,664 of the options vest on the thirteen (13) month anniversary of the grant date, and 1,664 of the options vest on each successive one-month anniversary thereafter for the next thirty five (35) months. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 21:47 UTC |
Ossipow VincentDirector
|
GrantStock Option · Derivative | 29,959 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001193805-19-000671 · e618567_4-ossipow.xml · derivative · entry 1 Ossipow Vincent · CIK 0001773679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2029-07-22 F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 21:48 UTC |
Neermann JoergDirector
|
GrantStock Option · Derivative | 29,959 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001193805-19-000672 · e618566_4-jorg.xml · derivative · entry 1 Neermann Joerg · CIK 0001773900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2029-07-22 F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 21:46 UTC |
Nash DuaneDirector
|
GrantStock Option · Derivative | 29,959 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001193805-19-000670 · e618564_4-duane.xml · derivative · entry 1 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2029-07-22 F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:50 UTC |
Cox Russell J.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 1,854,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000018 · wf-form4_154752058722280.xml · derivative · entry 2 Cox Russell J. · CIK 0001512984 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,854,376 Underlying: Common Stock · 1,854,376 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock. F4 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). F4 · derivative.expiration_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:50 UTC |
Cox Russell J.Director · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,588,832 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001280776-19-000018 · wf-form4_154752058722280.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,588,832 shares Expires 2028-01-02 F2 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F1 · derivative.exercise_date: Twenty five (25%) of the shares of common stock subject to the option vested on January 3, 2019, and thereafter, one forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly, such that all of the shares of common stock subject to the option are vested by January 3, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended & Restated 2017 Inducement Equity Incentive Plan (the "Plan)) through each vesting date; provided, that, the unvested portion of the option, if any, that would vest during the 12-month period following his termination date had he remained employed by the Issuer through such date shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:49 UTC |
Ashley Robert A.Chief Scientific Officer, EVP
|
GrantRestricted Stock Units · Derivative | 816,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000017 · wf-form4_154752054652794.xml · derivative · entry 7 Ashley Robert A. · CIK 0001591017 · Chief Scientific Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,634 Underlying: Common Stock · 816,634 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock. F6 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). F6 · derivative.expiration_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:49 UTC |
Ashley Robert A.Chief Scientific Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000017 · wf-form4_154752054652794.xml · derivative · entry 6 Ashley Robert A. · CIK 0001591017 · Chief Scientific Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-06-08 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F4 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:49 UTC |
Ashley Robert A.Chief Scientific Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-19-000017 · wf-form4_154752054652794.xml · derivative · entry 5 Ashley Robert A. · CIK 0001591017 · Chief Scientific Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-06-09 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F3 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:49 UTC |
Ashley Robert A.Chief Scientific Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001280776-19-000017 · wf-form4_154752054652794.xml · derivative · entry 4 Ashley Robert A. · CIK 0001591017 · Chief Scientific Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2026-05-12 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F2 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:49 UTC |
Ashley Robert A.Chief Scientific Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 241,670 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000017 · wf-form4_154752054652794.xml · derivative · entry 3 Ashley Robert A. · CIK 0001591017 · Chief Scientific Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 241,670 shares Expires 2022-09-25 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:49 UTC |
Ashley Robert A.Chief Scientific Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 23,344 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001280776-19-000017 · wf-form4_154752054652794.xml · derivative · entry 2 Ashley Robert A. · CIK 0001591017 · Chief Scientific Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,344 shares Expires 2022-04-24 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:49 UTC |
Ashley Robert A.Chief Scientific Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 93,377 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001280776-19-000017 · wf-form4_154752054652794.xml · derivative · entry 1 Ashley Robert A. · CIK 0001591017 · Chief Scientific Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,377 shares Expires 2022-03-31 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
Swanson Michael V.Chief Financial Officer, EVP
|
GrantRestricted Stock Units · Derivative | 817,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000016 · wf-form4_154752050707222.xml · derivative · entry 5 Swanson Michael V. · CIK 0001591694 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,826 Underlying: Common Stock · 817,826 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock. F6 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). F6 · derivative.expiration_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
Swanson Michael V.Chief Financial Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000016 · wf-form4_154752050707222.xml · derivative · entry 4 Swanson Michael V. · CIK 0001591694 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-06-08 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F4 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
Swanson Michael V.Chief Financial Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-19-000016 · wf-form4_154752050707222.xml · derivative · entry 3 Swanson Michael V. · CIK 0001591694 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-06-09 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F3 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
Swanson Michael V.Chief Financial Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001280776-19-000016 · wf-form4_154752050707222.xml · derivative · entry 2 Swanson Michael V. · CIK 0001591694 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2026-05-12 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F2 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
Swanson Michael V.Chief Financial Officer, EVP
|
Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000016 · wf-form4_154752050707222.xml · derivative · entry 1 Swanson Michael V. · CIK 0001591694 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2023-09-08 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
DUNN JOHN MICHAELGeneral Counsel and Secretary
|
GrantRestricted Stock Units · Derivative | 724,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000015 · wf-form4_154752047327275.xml · derivative · entry 5 DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,848 Underlying: Common Stock · 724,848 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock. F7 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). F7 · derivative.expiration_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
DUNN JOHN MICHAELGeneral Counsel and Secretary
|
Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000015 · wf-form4_154752047327275.xml · derivative · entry 4 DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2028-06-08 F2 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F5 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
DUNN JOHN MICHAELGeneral Counsel and Secretary
|
Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-19-000015 · wf-form4_154752047327275.xml · derivative · entry 3 DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2027-06-09 F2 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F4 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
DUNN JOHN MICHAELGeneral Counsel and Secretary
|
Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001280776-19-000015 · wf-form4_154752047327275.xml · derivative · entry 2 DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2026-05-12 F2 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F3 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:48 UTC |
DUNN JOHN MICHAELGeneral Counsel and Secretary
|
Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001280776-19-000015 · wf-form4_154752047327275.xml · derivative · entry 1 DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-11-16 F2 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F1 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of November 17, 2014, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:47 UTC |
Nash DuanePresident
|
GrantRestricted Stock Units · Derivative | 886,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000014 · wf-form4_154752044124186.xml · derivative · entry 7 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,316 Underlying: Common Stock · 886,316 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vital Therapies, Inc. Common Stock. F6 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). F6 · derivative.expiration_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), twenty five percent (25%) of the RSUs vest annually after the vesting commencement date of January 11, 2019. One hundred percent (100%) of the unvested portion of the RSUs, if any, shall vest in the event of a Termination without Cause or Resignation for Good Reason (each as defined in the reporting person's Change of Control and Severance Agreement). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:47 UTC |
Nash DuanePresident
|
Disposition to issuerCommon Stock · Derivative | 85,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000014 · wf-form4_154752044124186.xml · derivative · entry 6 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2028-06-08 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F4 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 9, 2018, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:47 UTC |
Nash DuanePresident
|
Disposition to issuerStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-19-000014 · wf-form4_154752044124186.xml · derivative · entry 5 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2027-06-09 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F3 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of June 10, 2017, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:47 UTC |
Nash DuanePresident
|
Disposition to issuerStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001280776-19-000014 · wf-form4_154752044124186.xml · derivative · entry 4 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2026-05-12 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. F2 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")), one forty-eighth (1/48th) of the shares subject to the option vested and became exercisable one month after the vesting commencement date of April 16, 2016, and an additional one forty-eighth (1/48th) of the shares vest and become exercisable at the end of each monthly period thereafter. One hundred percent (100%) of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:47 UTC |
Nash DuanePresident
|
Disposition to issuerStock Option (right to buy) · Derivative | 241,670 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001280776-19-000014 · wf-form4_154752044124186.xml · derivative · entry 3 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 241,670 shares Expires 2022-09-25 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:47 UTC |
Nash DuanePresident
|
Disposition to issuerStock Option (right to buy) · Derivative | 23,344 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001280776-19-000014 · wf-form4_154752044124186.xml · derivative · entry 2 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,344 shares Expires 2022-04-24 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 02:47 UTC |
Nash DuanePresident
|
Disposition to issuerStock Option (right to buy) · Derivative | 93,377 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001280776-19-000014 · wf-form4_154752044124186.xml · derivative · entry 1 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,377 shares Expires 2022-03-31 F1 · price: The option was cancelled by mutual agreement of the reporting person and Vital Therapies, Inc. The reporting person received a restricted stock unit award as reported in this Form 4 as consideration for this cancellation. Read SEC document |
| September 25, 2018 Filed Sep 25, 2018 23:28 UTC |
Halperin Errol R.Director
|
SaleCommon Stock | 10,000 | $0.29 | $2,900.00 |
DisclosureSEC source: 0001280776-18-000095 · wf-form4_153791811594828.xml · nonDerivative · entry 2 Halperin Errol R. · CIK 0001591095 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · ownership.nature: Shares held by Errol Halperin IRA FBO Errol Halperin. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.